SG/PUT/MODERNA/180/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 01:15:11 11/05/2024 am IST | ||
| 5.74 EUR | +10.17% |
|
| Current month | -11.01% | ||
| 1 month | -14.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/24/11 | 5.74 | +10.17% | 0 |
| 09/24/09 | 5.21 | -2.98% | 0 |
| 08/24/08 | 5.37 | -1.47% | 0 |
| 07/24/07 | 5.45 | +0.18% | 0 |
| 06/24/06 | 5.44 | +6.46% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 11, 2024 at 01:15 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SQ6LDL |
| ISIN | DE000SQ6LDL4 |
| Date issued | 20/12/2022 |
| Strike | 180 $ |
| Maturity | 21/06/2024 (42 Days) |
| Parity | 10 : 1 |
| Emission price | 3.98 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.74 € |
|---|---|
| Lowest since issue | 3.23 € |
| Spread | 0.03 € |
| Spread % | 0.51% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
122.7
USD
Average target price
139.4
USD
Spread / Average Target
+13.58%
- Stock Market
- Warrants
- Warrant
